← Patent-cliff monitor small molecule LIFYORLI (COPACKAGED) RELACORILANT
Loss of exclusivity December 2041 latest FDA-listed patent expiry
Drug detail Brand name LIFYORLI (COPACKAGED) Active ingredient RELACORILANT Strength 100MG;25MG Dosage form CAPSULE Route ORAL Modality Small molecule FDA approval March 2026 Marketing status RX
Listed patents Patent Expires Type 12152028 December 2041 product 11285145 May 2041 use U-4459 12589094 May 2041 use U-4459 11464764 April 2040 product 12514849 December 2039 product 11925626 December 2039 product 9273047 May 2033 use U-4459 10456392 May 2033 use U-4457 8859774 May 2033 substance, product 11576907 May 2033 substance, product
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.